Rusfertide

Rusfertide, developed by Protagonist Therapeutics and Takeda, achieved significant success in Phase 3 trial for polycythemia vera patients, demonstrating superior blood count control.

Protagonist Therapeutics' experimental drug rusfertide achieved primary efficacy endpoints in Phase 3 trial for polycythemia vera, demonstrating successful stabilization of red blood cells.

Protagonist Therapeutics secured a significant $165 million milestone payment for icotrokinra in Q4 2024, strengthening their financial position with total cash reserves of $559.2 million.

Rusfertide, a novel hepcidin mimetic, has shown promise in eliminating phlebotomy needs for 69.2% of polycythemia vera patients in the phase 2 REVIVE trial.

Protagonist Therapeutics' rusfertide demonstrates durable hematocrit control in Phase 3 trials for polycythemia vera, reducing the need for phlebotomy.